ELVN

Enliven Therapeutics Inc.

NASDAQ: ELVN · HEALTHCARE · BIOTECHNOLOGY

$39.59

-2.20% today

Updated 2026-06-05

Market cap

$2.81B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.64

Dividend yield

—

52W range

$15 – $49

Volume

1.0M

Market cap

$2.81B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-1.64

Dividend yield

—

52W range

$15 – $49

Volume

1.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

3/9

Piotroski F-Score

Weak

15.8

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →202 stocks currently score above 75

Price targets

Analyst target

$60.11

+51.83%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 15.84 — safe zone

+ Debt/equity 0.00x — low leverage

Risks

- Piotroski 3/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-19.29M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-37.66M	$-71.58M	$-89.02M	$-103.69M	$-23.63M
EPS	—	—	—	—	$-1.64
Free cash flow	$-32.69M	$-61.42M	$-73.24M	$-70.46M	$-19.29M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
ELVN	$2.81B	25	4.3	3.0	5.0	8.5	—	Avoid
LLY	$948.95B	78	10.0	10.0	5.0	6.0	—	Strong Buy
JNJ	$536.54B	59	4.7	9.0	3.3	6.0	-71.41%	Buy
ABBV	$380.57B	63	4.0	8.0	4.0	5.0	-55.64%	Buy
UNH	$343.21B	54	5.3	5.5	4.7	5.5	-26.61%	Buy
MRK	$285.64B	50	3.3	8.0	2.7	5.0	-49.34%	Hold

Smart narrative

Enliven Therapeutics Inc. trades at $39.59. Our Smart Value Score of 25/100 indicates the stock is weak. The company scores 3/9 on the Piotroski F-Score. With an Altman Z-Score of 15.84, it sits in the safe zone.

Frequently asked questions

What is Enliven Therapeutics Inc.'s stock price?

Enliven Therapeutics Inc. (ELVN) trades at $39.59.

Is Enliven Therapeutics Inc. overvalued?

Enliven Therapeutics Inc. carries a Smart Value Score of 25/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Enliven Therapeutics Inc. (ELVN)?

The 12-month analyst consensus target is $60.11, about 51.8% above the current $39.59. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Enliven Therapeutics Inc.'s Altman Z-Score is 15.84, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-21.79%

Beta0.40

50D MA$41.53

200D MA$27.77

Shares out0.06B

Float0.04B

Short ratio—

Avg volume1.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

ELVN vs LLY →ELVN vs JNJ →ELVN vs ABBV →Stock screener →